Targeted Agent Rova-T Active in Small-Cell Lung Cancer

This video discusses the phase I trial of rovalpituzumab (Rova-T) for the treatment of patients with small-cell lung cancer.

Currently, topotecan is the only US Food and Drug Administration (FDA)-approved agent for the treatment of relapsed small-cell lung cancer (SCLC).

In this video, Gregory P. Kalemkerian, MD, of the University of Michigan Health System, discusses a phase I trial of rovalpituzumab (Rova-T), a novel agent that targets DLL3 that has shown activity in the second-line treatment of patients with SCLC.

Kalemkerian gave a presentation on SCLC at the 2017 Multidisciplinary Thoracic Cancers Symposium, held March 16–18 in San Francisco.